Newly approved medication for subjects in early stages of treatment for Relapsing Remitting Multiple Sclerosis

A 12 month study comparing approved 1st line DMT vs Fingolimod in Relapsing Remitting MS patients.

  • 18-65
  • Patients naive to treatment OR who have been treated with no more than one DMT.
  • Strict cardiovascular exclusions.  All cardiac history will be reviewed by study nurse.
  • Patients without history of varicella or vaccination may screen 1 month after receiving vaccine.

Learn more about PrefererMS studies at www.rrmsresearchstudy.com